Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Those That Cannot Be Successful Raise Money

Executive Summary

It struck me last week that that the quote attributed to George Bernard Shaw – "He who can, does. He who cannot, teaches." – can be modified to apply to an increasing cadre of small- and mid-capitalization life science companies. Success for these companies that resonates with investors is either to be acquired or to reach a valuation that is too big to be acquired. The opposite of success is not so easy to define since clinical, regulatory or commercial failure usually means coming back to investors for a bail out.

You may also be interested in...



Amarin borrows $100m to launch Vascepa but keeps alliance door open

Amarin's stock price fell 18.4% to $9.75 per share in after-hours trading on 6 December after the company announced that it raised $100 million in non-equity financing from an investment fund managed by Pharmakon Advisors to support commercialization of its prescription fish oil pill Vascepa (icosapent ethyl) without a partner.

Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.

Stockwatch: Some Failed Drugs Never Die, They Just Find New Investors

Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel